BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 29076146)

  • 1. Bearing 19q13 aberration predicts poor prognosis in non-germinal centre type of CD5
    Mishima Y; Terui Y; Yokoyama M; Nishimura N; Ueda K; Kusano Y; Yamauchi H; Inoue N; Takahashi A; Tsuyama N; Mishima Y; Takeuchi K; Hatake K
    Br J Haematol; 2018 Nov; 183(4):661-664. PubMed ID: 29076146
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytogenetic features of de novo CD5-positive diffuse large B-cell lymphoma: chromosome aberrations affecting 8p21 and 11q13 constitute major subgroups with different overall survival.
    Yoshioka T; Miura I; Kume M; Takahashi N; Okamoto M; Ichinohasama R; Yoshino T; Yamaguchi M; Hirokawa M; Sawada K; Nakamura S
    Genes Chromosomes Cancer; 2005 Feb; 42(2):149-57. PubMed ID: 15543600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome-wide array-based comparative genomic hybridization of diffuse large B-cell lymphoma: comparison between CD5-positive and CD5-negative cases.
    Tagawa H; Tsuzuki S; Suzuki R; Karnan S; Ota A; Kameoka Y; Suguro M; Matsuo K; Yamaguchi M; Okamoto M; Morishima Y; Nakamura S; Seto M
    Cancer Res; 2004 Sep; 64(17):5948-55. PubMed ID: 15342373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic significance and therapeutic implication of de novo CD5+ diffuse large B-cell lymphoma.
    Tang H; Zhou H; Wei J; Liu H; Qian W; Chen X
    Hematology; 2019 Dec; 24(1):446-454. PubMed ID: 31072235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Diffuse Large B-Cell Lymphoma.
    Miyazaki K
    J Clin Exp Hematop; 2016; 56(2):79-88. PubMed ID: 27980306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IRF8 is associated with germinal center B-cell-like type of diffuse large B-cell lymphoma and exceptionally involved in translocation t(14;16)(q32.33;q24.1).
    Tinguely M; Thies S; Frigerio S; Reineke T; Korol D; Zimmermann DR
    Leuk Lymphoma; 2014 Jan; 55(1):136-42. PubMed ID: 23573829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma.
    Obermann EC; Csato M; Dirnhofer S; Tzankov A
    J Clin Pathol; 2009 Oct; 62(10):903-7. PubMed ID: 19783718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel IGH and MYC Translocation Partners in Diffuse Large B-Cell Lymphomas.
    Otto C; Scholtysik R; Schmitz R; Kreuz M; Becher C; Hummel M; Rosenwald A; Trümper L; Klapper W; Siebert R; Küppers R;
    Genes Chromosomes Cancer; 2016 Dec; 55(12):932-943. PubMed ID: 27356265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.
    Yoon SO; Jeon YK; Paik JH; Kim WY; Kim YA; Kim JE; Kim CW
    Histopathology; 2008 Aug; 53(2):205-17. PubMed ID: 18752503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
    Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N
    Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
    Tsuyama N; Ennishi D; Yokoyama M; Baba S; Asaka R; Mishima Y; Terui Y; Hatake K; Takeuchi K
    Oncotarget; 2017 May; 8(20):33487-33500. PubMed ID: 28380441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1.
    Hoeller S; Schneider A; Haralambieva E; Dirnhofer S; Tzankov A
    Histopathology; 2010 Jul; 57(1):73-80. PubMed ID: 20579129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients.
    Yamaguchi M; Nakamura N; Suzuki R; Kagami Y; Okamoto M; Ichinohasama R; Yoshino T; Suzumiya J; Murase T; Miura I; Ohshima K; Nishikori M; Tamaru J; Taniwaki M; Hirano M; Morishima Y; Ueda R; Shiku H; Nakamura S
    Haematologica; 2008 Aug; 93(8):1195-202. PubMed ID: 18556402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of chromosomal imbalances in de novo CD5-positive diffuse large-B-cell lymphoma detected by comparative genomic hybridization.
    Karnan S; Tagawa H; Suzuki R; Suguro M; Yamaguchi M; Okamoto M; Morishima Y; Nakamura S; Seto M
    Genes Chromosomes Cancer; 2004 Jan; 39(1):77-81. PubMed ID: 14603444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort.
    Alinari L; Gru A; Quinion C; Huang Y; Lozanski A; Lozanski G; Poston J; Venkataraman G; Oak E; Kreisel F; Park SI; Matthews S; Abramson JS; Iris Lim H; Martin P; Cohen JB; Evens A; Al-Mansour Z; Singavi A; Fenske TS; Blum KA
    Am J Hematol; 2016 Jun; 91(4):395-9. PubMed ID: 26800311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression profiling of diffuse large B-Cell lymphomas supervised by CD5 expression.
    Miyazaki K; Yamaguchi M; Imai H; Kobayashi K; Tamaru S; Kobayashi T; Shiku H; Katayama N
    Int J Hematol; 2015 Aug; 102(2):188-94. PubMed ID: 26009281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome.
    Kojima Y; Tsurumi H; Goto N; Shimizu M; Kasahara S; Yamada T; Kanemura N; Hara T; Sawada M; Saio M; Yamada T; Takahashi T; Tomita E; Takami T; Moriwaki H
    Eur J Haematol; 2006 Jun; 76(6):465-72. PubMed ID: 16494623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytogenetic analysis of de novo CD5-positive diffuse large B-cell lymphoma.
    Kaneko H; Shimura K; Horiike S; Kuroda J; Matsumoto Y; Yokota S; Nishida K; Ohkawara Y; Taniwaki M
    Asia Pac J Clin Oncol; 2011 Dec; 7(4):346-50. PubMed ID: 22151983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH.
    Thakral B; Medeiros LJ; Desai P; Lin P; Yin CC; Tang G; Khoury JD; Hu S; Xu J; Loghavi S; Hu B; Oki Y; Li S
    Eur J Haematol; 2017 Apr; 98(4):415-421. PubMed ID: 28039906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of somatic quantitative genetic alterations by multiplex polymerase chain reaction for the prediction of outcome in diffuse large B-cell lymphomas.
    Jardin F; Ruminy P; Kerckaert JP; Parmentier F; Picquenot JM; Quief S; Villenet C; Buchonnet G; Tosi M; Frebourg T; Bastard C; Tilly H
    Haematologica; 2008 Apr; 93(4):543-50. PubMed ID: 18287131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.